{"schema_version":"secwatch.filing_event.v1","accession":"0001156039-25-000142","form_type":"8-K","ticker":"ELV","cik":"0001156039","company_name":"Elevance Health, Inc.","filed_at":"2025-12-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.893681+00:00","generated_at":"2026-05-16T13:37:17.597921+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Elevance Health elects Amy Schulman as independent director effective Jan 12, 2026","bullets":["Amy Schulman, Managing Partner at Polaris Partners, joins Elevance Health board.","Appointed to Audit and Finance Committees; effective January 12, 2026.","Schulman also chairs Alnylam Pharmaceuticals board and is senior lecturer at Harvard Business School.","Board cites ongoing refreshment strategy; Schulman brings healthcare, governance, and investment expertise."],"urls":{"canonical":"https://secwatch.observer/filing/0001156039-25-000142","json":"https://secwatch.observer/filing/0001156039-25-000142.json","markdown":"https://secwatch.observer/filing/0001156039-25-000142.md","text":"https://secwatch.observer/filing/0001156039-25-000142.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1156039/000115603925000142/0001156039-25-000142-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1156039/000115603925000142/elv-20251210.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:37:17.597921+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}